RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
======================================================================================================================================================================================================================

* Romain Cohen
* Jaafar Bennouna
* Aurélia Meurisse
* Christophe Tournigand
* Christelle De La Fouchardière
* David Tougeron
* Christophe Borg
* Thibault Mazard
* Benoist Chibaudel
* Marie-Line Garcia-Larnicol
* Magali Svrcek
* Dewi Vernerey
* Yves Menu
* Thierry André